TY - JOUR AU - Sieg, Maximilian AU - Hartmann, Michael AU - Settmacher, Utz AU - Arefian, Habibollah PY - 2020 DA - 2020/04/21 TI - Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States JO - BMC Gastroenterology SP - 120 VL - 20 IS - 1 AB - Cabozantinib was approved by the European Medicines Agency and the Federal Drug Administration as an option for sorafenib-resistant advanced hepatocellular carcinoma, increasing overall survival and progression-free survival compared with placebo. We evaluated the cost-effectiveness of cabozantinib in the second-line setting for patients with an advanced hepatocellular carcinoma from the German statutory health insurance perspective compared with an US scenario using US prices. SN - 1471-230X UR - https://doi.org/10.1186/s12876-020-01241-y DO - 10.1186/s12876-020-01241-y ID - Sieg2020 ER -